Labcorp’s Financial Performance Shows Resilience Amid Market Fluctuations
Burlington, North Carolina-based Labcorp Holdings Inc. (LH) is a significant player in laboratory services, offering a wide range of tests, including blood chemistry analyses, urinalyses, thyroid tests, PAP, and substance abuse evaluations. With a market capitalization of $19.6 billion, Labcorp operates in two main segments: Diagnostics Laboratories and Biopharma Laboratory Services.
Companies valued at $10 billion or more are classified as “large-cap stocks.” Labcorp, with its considerable market cap, falls into this category, reflecting its substantial size and influence in the competitive diagnostics and research industry.
Active Investor: FREE newsletter going behind the headlines on the hottest stocks to uncover new trade ideas
Labcorp reached a two-year high of $258.59 on March 5 and is currently trading 9.8% below that peak. Over the past three months, LH shares rose nearly 1%, while the Nasdaq Composite index ($NASX) saw a decline of 10.6% during the same period.
In a longer view, Labcorp’s stock increased by 6% over the last six months, significantly outperforming the Nasdaq’s dip of 1.6%. Over the past year, LH has posted a 9.3% gain, slightly trailing the Nasdaq’s 9.7% returns.
To support this upward trend, Labcorp has maintained trading primarily above its 200-day moving average since late July of the previous year. However, it dropped below its 50-day moving average during the second week of March.
Following the release of its mixed Q4 results on February 6, Labcorp’s stock saw a slight decline. The company experienced robust organic and inorganic revenue growth, with total revenue climbing 9.8% year-over-year to $3.3 billion, surpassing analysts’ expectations. However, challenges arose as higher costs led to a 16 basis point decrease in gross margin to 26.9%. An 11.7% rise in selling, general, and administrative (SG&A) expenses also impacted Labcorp’s adjusted operating margin. Nevertheless, adjusted net income rose modestly by 2.9% year-over-year to $290.4 million, with adjusted earnings per share (EPS) of $3.45 exceeding expectations by 1.5%.
Looking ahead, Labcorp’s CEO Adam Schechter expresses optimism for strong growth and margin expansion in both segments by 2025.
In comparison to its peers, Labcorp has outperformed Waters Corporation (WAT), which gained 3.4% over the past six months and 8.8% over the past year.
Among the 16 analysts covering Labcorp’s stock, the consensus rating is a “Strong Buy.” The average price target of $278.06 indicates a potential upside of 19.2% from current levels.
On the date of publication, Aditya Sarawgi did not hold positions (either directly or indirectly) in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. For more information, please view the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
